• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
  • For Subscribers

Trendingnow

1

Social Security has less than 6 years before a 22% cut. A Senate chairman’s fix is to borrow $190 trillion and call it the ‘Stop Scaring Seniors Act’

2

Sound Ventures turned $435 million into a $7 billion Anthropic stake. Ashton Kutcher left months before the IPO

3

Anthropic’s IPO is set to make the average employee worth over $40 million—and at least 400 early hires will be worth $100 million or more

1

Social Security has less than 6 years before a 22% cut. A Senate chairman’s fix is to borrow $190 trillion and call it the ‘Stop Scaring Seniors Act’

2

Sound Ventures turned $435 million into a $7 billion Anthropic stake. Ashton Kutcher left months before the IPO

3

Anthropic’s IPO is set to make the average employee worth over $40 million—and at least 400 early hires will be worth $100 million or more
Healthbiogen

Why Biogen Is Poaching This Pfizer Exec to Head Up Its R&D Shop

By
Sy Mukherjee
Sy Mukherjee
Down Arrow Button Icon
By
Sy Mukherjee
Sy Mukherjee
Down Arrow Button Icon
April 27, 2016, 10:49 AM ET
547016547
Doctor and nurse examining CT scan digital tabletPhotograph by Hero Images—Getty Images
Google source logo
Add Fortune on Google for similar content.

Large-cap biotech Biogen (BIIB) has finally landed itself a new R&D chief after a months-long vacancy in the position, the company announced on Wednesday. The job will go to Michael Ehlers, who is currently a senior VP and chief scientific officer of the neuroscience unit at pharma giant Pfizer (PFE).

Ehlers’ appointment meshes with Biogen’s new focus on therapies for central nervous system disorders. Last year, the company lopped off 11% of its global workforce to secure savings that it could then siphon into more aggressive drug discovery and development efforts for conditions like Alzheimer’s disease and spinal muscular atrophy.

Biogen CEO George Scangos addressed Ehlers’ compatibility with the firm’s forward-looking therapeutic focus in a statement.

“Mike is a brilliant neuroscientist, having made major contributions to our understanding of the biology of neurons,” he said. “He is an established R&D leader who has excelled in both academic and corporate settings, and he has demonstrated the ability to translate science into important new medicines.”

 

Ehlers is slated to begin at Biogen in late May after a six-year run with Pfizer, and his official title in the new role will be Executive Vice President of Research and Development.

He’ll have his work cut out for him. While Biogen’s experimental Alzheimer’s therapy aducanumab has shown promise in early-stage patients, developing successful drugs for neurodegenerative diseases is one of the toughest challenges facing biotech and pharmaceutical companies.

About the Author
By Sy Mukherjee
See full bioRight Arrow Button Icon

Latest in Health


Most Popular

Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • TikTok icon
  • YouTube icon

    Recommended For You

    © 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
    FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.